More than 4000 children are missing out on hormone treatmentBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7349.1294/a (Published 01 June 2002) Cite this as: BMJ 2002;324:1294
- Susan Mayor
The UK National Institute for Clinical Excellence (NICE) has advised that human growth hormone (somatropin) is clinically effective and cost efficient in the management of children with growth hormone deficiency.
It estimates that more than 4000 more children could benefit from the drug than the 1600 who are receiving it in England and Wales at present.
The institute has recommended that biosynthetic human growth hormone should be used in the treatment of children with growth hormone deficiency, Turner's syndrome, and Prader-Willi syndrome, and in prepubertal children with chronic renal insufficiency.